Abstract: A deodorant composition comprising a metal oxide; a primary emollient; and at least one wax with a melting point above 50° C.: wherein the composition is anhydrous and aluminum-free; and wherein the composition has a pH greater than about 8.0 at 60 minutes as measured by the pH Release Test Method.

Abstract: The invention discloses persistent antimicrobial protection of hands and/or surfaces of different objects using the hydro-alcoholic gel composition of the present invention. In particular, the invention provides water-resistant sanitizing hydro-alcoholic gel compositions based on ethyl alcohol, silver nanoparticles and fatty acids of Tung seed oil (Aleurites fordii). More particularly, it discloses the compositions that keep the surface sanitized well beyond the instant sanitization provided by volatile ethyl alcohol. The compositions of the present invention have ‘natural origin’ index of minimum 99% as per ISO 16128-2.

Abstract: The present invention relates to methods for preparing compositions comprising calcium and fluoride, and, in particular, to methods for preparing compositions comprising calcium that is stabilised with a stabilising agent and fluoride. For example, the method is for the preparation of compositions comprising amorphous calcium phosphate stabilised by phosphopeptides, and free fluoride. The invention also extends to various compositions produced by such methods, including oral care products.

Abstract: An oral care composition having a soluble zinc polyphosphate complex made by combining ingredients including an inorganic zinc salt, and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of treating a subject suffering from dentinal sensitivity applying the oral care composition to the teeth and gums of the subject.

Abstract: The present invention relates to a process for semi-permanent straightening and permanent shaping hair, especially human hair, for improved and milder semi-permanent straightening and permanent shaping. It is found out that when commonly used permanent shaping reducing composition is mixed with another composition comprising predominantly carboxylic acids, the permanent shaping effect of the composition is improved, homogeneous shaping of hair fibers is achieved and natural cosmetic properties of hair is maintained and hair may be semi-permanently straightened before such process.

Abstract: The disclosure relates to compositions for altering the color of keratin fibers and methods of using the compositions. The compositions comprise (a) a bonding system comprising (i) at least one first bonding agent chosen from lactic acid and/or salts thereof, and (ii) at least one second bonding agent chosen from amino acids and/or salts thereof; (b) at least one fatty alcohol; (c) at least one fatty acid; (d) at least one alkyl polyglucoside; (e) at least one alkalizing agent; and (f) at least one solvent. The compositions can further comprise one or more oxidation dyes, couplers, oxidizing agents, or combinations thereof.

Abstract: Provided is a sulfate-free surfactant system which is particularly suitable for use in personal hygiene products. The sulfate-free surfactant system comprises a liquid comprising an organic phase and a solvent wherein the organic phase comprises glyceride and surfactant and the liquid comprises: 4-40 wt % glyceride wherein the glyceride is the condensation reaction product of at least 1.10 moles of a mixture of acids to no more than 2.1 moles of mixture of acids per mole of glycerin; wherein mixture of acids comprises: at least 0.275 to no more than 0.990 moles of a first acid comprising a branched acid with 16-20 aliphatic carbons; at least 0.250 to no more than 0.810 moles of a second acid comprising an alkyl acid with 9-11 carbons; and at least 0.250 to no more than 0.810 moles of a third acid comprising an alkyl acid with 7-9 carbons wherein the third acid has a lower molecular weight than the second acid; and 6-45 wt % surfactant; and wherein the liquid has a BYV of at least 50 dyn/cm2.

Abstract: The present disclosure relates to compositions for altering the tone or color of the hair comprising at least one amino acid, at least one carboxylic acid, monoethanolamine, at least one oxidation base chosen from toluene-2,5-diamine, acid salts thereof, or solvates thereof, and a coupler system comprising one or more couplers chosen from 2,4-diaminophenoxyethanol, meta-aminophenol, derivatives thereof, addition salts thereof, solvates thereof, solvates of salts thereof, or mixtures thereof. The disclosure also relates to methods of using the compositions and kits comprising the compositions.

Abstract: Hair shine compositions are disclosed. In embodiments, a hair shine composition may include greater than or equal to 50 wt/wt % and less than or equal to 95 wt/wt % water; greater than or equal to 0.5 wt/wt % and less than or equal to 3 wt/wt % propanediol; and greater than or equal to 0.25 wt/wt % and less than or equal to 2 wt/wt % dimethyl isosorbide. In embodiments, a wt/wt % ratio of propanediol to dimethyl isosorbide may be from 1.00:1 to 3.00:1.

Abstract: The subject of the present application is an agent for the oxidative dyeing of keratinous fibers, in particular human hair, which contains the coupling oxidation dye precursor 2-(1,3-benzodioxol-5-ylamino)ethanol in combination with the oxidation base 2-methoxymethyl-para-phenylenediamine.

Abstract: The present invention relates to pharmaceutical compositions and their use in oral hygiene. More particularly, the compositions comprise one or more flavonoids, such as naringin and neohesperidine and polylysine and/or caprylic acid and/or a zinc salt. Such compositions may be in the form of, for example, a solution, gel, spray, chewing gum or paste suitable for use in the oral cavity. The composition may be used in reducing bacterial numbers on teeth, gums or other surfaces in the oral cavity.

Abstract: The instant disclosure relates to a cosmetic composition containing high amounts of lactone polyols and to methods for treating skin with the compositions. The cosmetic compositions include: (a) poly C10-30 alkyl acrylate; (b) at least 5 wt. % of one or more lactone polyols; (c) one or more nonionic emulsifiers; (d) one or more fatty compounds; and (e) water. In addition, the amount of the one or more lactone polyols in the composition is typically at least 10-fold higher than the amount of the poly C10-30 alkyl acrylate in the composition.

Abstract: The present disclosure provides an oily moisturizer composed of an esterified product of a component A and a component B, or an esterified product of the component A, the component B and a component C, wherein Component A comprises a polyhydric alcohol that is dipentaerythritol, erythritol or sorbitan, Component B comprises one fatty acid, or two or more fatty acids, selected from among linear saturated fatty acids of 6 to 10 carbon atoms, and Component C comprises one fatty acid, or two or more fatty acids, selected from among fatty acids of 6 to 28 carbon atoms (but excluding fatty acids of the component B).

Abstract: The invention relates to a cosmetic composition comprising a low molecular weight silk fibroin and a cosmetically acceptable carrier; wherein said low molecular weight silk fibroin comprises at least 85 parts by weight peptides of molecular weight less than 2500 Da, where amino acid sequence of at least 50 wt % of said peptides is GAGY, GAGAGAGY, GAGVGAGY or AWSSESDF and where said silk fibroin is produced by a process comprising the steps of: (i) mixing an aqueous solution comprising 0.01 to 20 wt % of a high molecular weight silk fibroin of weight average molecular weight 6 to 100 KDa with ochymotrypsin at temperature of 25 to 45° C.

Abstract: The present disclosure relates to a peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, a pharmaceutical composition for preventing or treating skin disease including the peptide, a cosmetic composition for skin condition improvement including the peptide, a food composition for skin condition improvement including the peptide, a method of preventing or treating skin disease using the peptide, and a use of the peptide in preventing or treating skin disease or improving skin condition.

Abstract: The disclosure relates to a process for treating keratin fibers comprising, in a first stage, the application to said fibers of an oily dispersion (A) comprising i) particles of copolymers of alkyl acrylates and anhydride acrylics, ii) stabilizers, and iii) one or more hydrocarbon-based oils, and then, in a second stage, the application to said fibers of a composition (B) comprising iv) one or more amine compounds; or the application to said fibers of an oily dispersion (D) comprising said ingredients i), ii), iii) and iv), wherein v) one or more dye(s) and/or pigment(s) may be in the dispersion (A) or (D), in a composition (B), and/or in another composition (C). The disclosure further relates to a multi-compartment kit comprising the ingredients i) to v), and an oily dispersion (A) comprising v) the one or more dyes and/or pigments.

Abstract: A process and a kit-of-parts for dyeing keratinous material, in particular human hair, are provided. An exemplary process includes applying a pre-treatment agent (V) to the keratinous material, wherein the pre-treatment agent in a cosmetic carrier includes at least one oxidizing agent (V-1), and applying a colorant (F) to the keratinous material, the colorant being in a cosmetic carrier and including (F-1) at least one amino-functionalized silicone polymer and (F-2) at least one pigment.

Abstract: Cosmetic and/or pharmaceutical compositions for promoting hair growth by modulating the expression of genes involved in the JAK-STAT signaling pathway are provided. The compositions include at least one plant lipid, preferably pataua (Oenocarpus bataua) oil. Also included are methods for promoting hair growth by modulating the expression of genes involved in the JAK-STAT signaling pathway.

Abstract: The present invention relates to a method of preparing an enzyme-treated Zizania latifolia Turcz. extract and a composition prepared therefrom, and the enzyme-treated Zizania latifolia Turcz. extract prepared by the above method contains a high content of tricin, and thus it can be usefully used as a cosmetic composition or a health functional food composition for whitening, wrinkle improvement, anti-inflammatory, anti-allergy and moisturizing.

Abstract: Provided are formulations and methods for treating one or more genitourinary conditions. The formulations may include a therapeutic agent that includes a calcium channel blocker, a rho kinase inhibitor, or a combination thereof. The methods may include locally administering a therapeutic agent into a ureter. Systems for delivering a therapeutic agent also are provided.

Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Abstract: Disclosed herein are ionic liquid composition(s) of amphotericin B comprising amphotericin B; a complexing agent component; a solvent component comprising acidified solvent(s); and a solubilizing component. Disclosed composition(s) comprise at least two complexing agents and two or more constituents of the composition provide two or more functional activities. Ionic liquid composition(s) disclosed are in aspects provided as oral dissolve film(s) useful in the treatment of oral microbial infection(s), e.g., oral candidiasis. Disclosed ionic liquid composition(s) of amphotericin B and ODF(s) thereof have a solubility of amphotericin B in water of at least 3 mg/mL.

Abstract: The present invention provides an oral patch for localized treatment of mouth ulcers containing combination of tetracaine and triamcinolone as active drugs. The patch is a bilayer structure containing a drug layer with amorphous tetracaine hydrochloride and amorphous triamcinolone acetonide and a water-soluble backing layer without a drug. The oral patch with combination of drugs has improved efficacy over each individual drug. The drug layer comprises 3-20% by weight of amorphous tetracaine hydrochloride, or a pharmaceutical acceptable salt thereof, 0.1-2.0% by weight of amorphous triamcinolone acetonide or a pharmaceutical acceptable salt thereof, 20-95% by weight of a first film-forming material, 1-12% by weight of an adhesive, 1-20% by weight of one or more cooling agent, and optionally 1-12% by weight of a plasticizer. The backing layer comprises 70-95% by weight of one or more film-forming agents, 2-10% by weight of a plasticizer and optionally 1-8% by weight of a flavoring agent.

Abstract: The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present disclosure provides compositions and methods for controlled release of macromolecules (such as proteins and polypeptides). The present disclosure also provides method for preparing and using the same.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Abstract: A method of generating an internally fixed lipid vesicle, comprising: providing a precursor lipid vesicle that contains an aqueous interior enclosed by a lipid membrane, wherein the lipid membrane of the precursor lipid vesicle is non-permeable to a crosslinker; permeabilizing the lipid membrane transiently to generate a permeable vesicle; contacting the permeable vesicle with an inactive activatable crosslinker, whereby the inactive activatable crosslinker enters the permeable vesicle; allowing the permeable vesicle to return to a non-permeable vesicle; removing any extravesicular crosslinker; and activating the inactive activatable crosslinker to allow crosslinking to occur inside the non-permeable vesicle, whereby an internally fixed lipid vesicle is generated.

Abstract: Exosomes comprising a modified RNA are disclosed. Aspects of the disclosure further relate to methods and compositions for using exosomes comprising a modified RNA. In certain aspects, the exosomes disclosed herein may be useful in delivering a modified RNA to a cell. In certain aspects, the exosomes disclosed herein may be useful in treating or preventing a disorder in a subject. Methods and compositions for producing the disclosed exosomes are also provided.

Abstract: System and methods related to lyophilization of pharmaceutical products are disclosed. In some embodiments, vials of product are moved through a system using one or more movers which are electromagnetically levitated and moved through the system without making mechanical contact with each other or the system. Load lock chambers may allow a mover to enter from one process region's environment and then be brought to an environment condition of the next process region to allow materials to be passed through conditioning, nucleation, and/or vacuum drying regions prior to finally exit the system to an unloading zone. The movers may then be cleaned or reloaded with vials to begin the process again with a new load of vials.

Abstract: An oral tablet for taste masking of active ingredients includes a population of particles and an active ingredient with off-note taste. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.

Abstract: A soluble fiber lozenge in includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives in the soluble-fiber matrix. A soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. Soluble fiber in soluble fiber lozenge can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges.

Abstract: A soft capsule film composition, comprising: (A) a native gellan gum; (B) one or more hydrophilic polysaccharides; (C) a starch or modified starch; (D) a plasticizer; and (E) water, wherein a gelling agent other than the native gellan gum and the one or more hydrophilic polysaccharides is not an essential component. The soft capsule film composition shortens drying time at room temperature, suppresses the stickiness of the surface of a film sheet, imparts film sheet strength which can withstand continuous production in factory manufacturing with a rotary die filling machine or the like, and enables the manufacture of a good soft capsule with high adhesiveness. For this reason, the soft capsule produced using the soft capsule film composition can be utilized for various uses such as drugs, quasi drugs, cosmetics, and foods.

Abstract: A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

Abstract: Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.

Abstract: Disclosed herein are electrospun fibrous matrix and its production method. The method mainly includes the steps of, mixing a first polymer and a drug to form a first mixture, and sonicating the first mixture until a plurality of microparticles are formed with the drug encapsulated therein; and mixing the plurality of microparticles with a second polymer to form a second mixture, subjecting the second mixture to a wet electrospinning process to form the electrospun fibrous matrix. The thus-produced electrospun fibrous matrix is characterized by having a plurality of first and second fibrils woven together, in which each second fibril has a plurality of drug-encapsulated microparticles independently integrated and disposed along the longitudinal direction of the second fibril. Also disclosed herein is a method for treating a wound of a subject. The method includes applying the present electrospun fibrous matrix to the wound of the subject.

Abstract: Devices, groups of devices, kits, and methods for using the devices and kits to administer a local anesthetic to a port site to numb the site prior to infusion or blood draw are described. The devices contain a flexible material with an adhesive coating on one side and a compartment for containing the medication. The device can be pre-filled or a fillable device. In fillable devices, the local anesthetic is transferred from a container into the compartment of the device via the inlet after the device is applied to the patient's skin. In pre-filled devices, the local anesthetic is inside the compartment and is covered with a removable layer to keep it sterile until use. When applied to the patient's skin, the device conforms to the surface of the patient's skin forming a seal keeping the medication in contact with port site.

Abstract: Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.

Abstract: A facial mask having pathogen inactivation capabilities is disclosed. One embodiment comprises a mask and a pathogen inactivation system coupled to the mask. The pathogen inactivation system is configured to heat and inactivate bacteria and viruses.

Abstract: Disclosed is a system and method for reducing microorganisms. The system comprises a light assembly and a processor. The light assembly operable to emit at least two of three different blue lights at different peak wavelengths with a full width half maximum of at most 25 nm, each peak having a time averaged intensity. The peak wavelengths are selected from 400-410 nm, 440-464 nm and 465-490 nm. The processor is communicably coupled to the light assembly to control the time averaged intensities of the blue lights emitted by the light assembly such that if two blue lights are used, the time averaged intensity of one blue light is between 0.67 and 1.33 times the time averaged intensity of another blue light; and if three blue lights are used, the time averaged intensity of any one blue light is between 0.76 and 1.24 times the time averaged intensity of the time averaged intensity of both the other blue lights.

Abstract: A germicidal device includes a lighting member operably in an on-state in which the lighting member emits ultraviolet light for killing microorganisms, or in an off-state in which the lighting member emits no light; a sensing member operably detecting at least one event occurred in an area; and a microcontroller unit coupled with the lighting member and the sensing member for controlling operations of the lighting member in a respective state in accordance with the at least one event occurred in the area. The at least one event includes a movement in the area, an acoustic wave in the area, an intrusion into the area, an expiration of an on-state time period in which the lighting member is in the on-state, an expiration of an off-state time period in which the lighting member is in the off-state, and/or an instruction from a remote operation.

Abstract: An overhead lighting fixture containing both visible light sources and UV light sources is disclosed herein. UV light can sanitize/disinfect the surrounding environment after the environment over a period of about 30-45 minutes. In this way, viruses, germs, bacteria, mold, and the like can be destroyed to clean the air and/or surfaces (e.g., furniture). Accordingly, embodiments of the present invention provide a controllable UV lighting assembly that can produce UV light to sanitize/disinfect an area and can be automatically disabled to prevent UV light exposure to those in the area using a motion sensor. The lighting assembly can produce visible light while the UV light source is disabled. According to some embodiments, the duration of UV light production is controlled by a timer for power savings.

Abstract: Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described.

Abstract: The invention relates to a coating for an implant component, a method for producing an implant component having said coating, and a use of said coating on an implant component. The coating is intended for an implant component, in particular a spinal implant component, and is a TiNb coating which has, in addition to an atom % proportion of Ti and an atom % proportion of Nb, an atom % proportion of 5-30 atom % of Ag.

Abstract: Compositions and methods thereof include bone fibers made from cortical bone in which a plurality of bone fibers are made into shapes that are used to augment fixation of orthopedic implants and screws. Sheets of bone fibers may be used as an interface between bone and tissue, tendons, and/or ligaments. Cylindrical shaped implants that may be placed in drilled holes in bone prior to screw placement to enhance fixation of the screw. The physical presence of the fibers provides initial fixation, while the use of an osteoinductive material provides long term enhancement of bone formation around the screw and hence fixation. The bone fiber compositions may be in the form of a cylinder or a tube. A delivery system and methods of use are also provided.

Abstract: The present disclosure relates generally to an osteo-tissue graft capable of promoting bone tissue growth and regeneration, comprising at least one self-assemble peptide and mesenchymal stem cells (MSCs) in accordance with the present invention and a method of preparing such an osteo-tissue graft. The grafts are suitable for treatment of bone disorder or damages through tissue engineering, cellular replacement therapies as well as other applications.

Abstract: A medical implant includes a first implant body and a pre-coating covering at least a portion of an outer surface of the first implant body. The pre-coating has a negative Poisson's ratio. A method of making a medical implant includes applying a precursor material on a surface of a first implant body, the first implant body having a positive Poisson's ratio.

Abstract: The approach described herein uses the spatially and temporally controlled growth for programming 3D shapes and their motions, possibly with an unlimited number of degrees of freedom, could thus create dynamic 3D structures. The ability to program growth-induced 3D shapes and motions could transform the way engineering systems, such as robots, actuators, and artificial muscles, are designed. The concept is applicable to other programmable materials. The 2D printing approach for 3D material programming represents a scalable and customizable 3D manufacturing technology, which can potentially be integrated with biological systems and existing 2D fabrication methods and devices for broader applications.

Abstract: The invention relates to a scaffold material comprising a plurality of particles of a highly porous polymeric material, characterized in that said scaffold material becomes a shapeable paste once hydrated. The specific features of the particle material impart a special behavior to the scaffold, which can be easily shaped and even highly reversibly compressed, so that in certain aspects it can, if needed, be injected, said capacity to be shaped being maintained over a high range of hydration conditions. A particular aspect of the invention relates, therefore, to the use of such scaffold material for the manufacturing of shapeable body implants, such as breast implants, to the shapeable body implants themselves as well as to non-invasive methods for using thereof in creating or reconstructing a three-dimensional volume in a subject's body part.

Abstract: A medical device includes a resin base including one or more than one material selected from a group consisted by an ethylene propylene resin containing fluorine, a styrene resin containing fluorine, an olefin resin containing fluorine, a vinyl chloride resin containing fluorine, a polyester resin containing fluorine, a polyurethane resin containing fluorine, and a nylon resin containing fluorine; an underlayer formed on the resin base, the underlayer including an oxazolidone ring; and an epoxy resin layer formed on the underlayer.